Leverage & Capital Structure
Q: What leverage ratio is acceptable?
A: Management is maintaining a disciplined approach in today’s higher rate environment, comfortable around 3.0x leverage with current net leverage at 2.08x. "

Acquisition Integration
Q: How will Cook integration affect margins?
A: They plan to integrate Cook’s sales team and shift manufacturing under a TSA, expecting the acquisition to be accretive to non‐GAAP margins in its first full year. "

Cook Synergy Impact
Q: Does the Cook deal add halo benefits?
A: The acquisition is seen as anchoring the portfolio, driving about $40 million annualized revenue and leveraging global synergies across the U.S. and Europe. " "

WRAPSODY Reimbursement Pricing
Q: Will WRAPSODY be priced at a premium?
A: Management confirmed that with the NTAP submission, they are pricing WRAPSODY as if the premium applies, though final details await FDA approval. " "

OEM Business Outlook
Q: Could OEM challenges affect future revenue?
A: Supply chain issues were discrete in Q3 and are not expected to persist, with guidance still targeting around 7% growth in OEM sales. "

Cash Flow & Capital Deployment
Q: How will strong cash flow be used?
A: With robust free cash flow performance, management intends to prudently deploy cash for further strategic acquisitions and investments. "

Sales Force Capability
Q: Can current sales teams handle new therapeutic products?
A: They are confident their trained sales force, already experienced in physician-preference products, will effectively support launches like WRAPSODY. "

Product Pipeline Strategy
Q: What about products beyond WRAPSODY?
A: While specifics remain under wraps, ongoing product development is a priority to sustain growth under the broader CGI strategy. "

FDA Communication Status
Q: Any issues with the FDA review process?
A: There have been no stoppages during the 180-day review period, keeping the process on track for WRAPSODY’s approval. "

Online Interest in WRAPSODY
Q: Is there increased online interest in WRAPSODY?
A: Although not measured in detail, management noted positive buzz and inquiry trends driven by emerging clinical data. "

SKU Rationalization & Margins
Q: Any further SKU rationalization planned?
A: The focus remains on replacing legacy products with efficient new versions, supporting continued margin improvements without major exits expected in 2025. "

China Market Trends
Q: How is China’s market performing amid VBP?
A: Management reported resilient performance with strong unit growth in China despite the pressures of volume-based purchasing. "

WRAPSODY Launch Timing
Q: Can WRAPSODY launch quickly post-approval?
A: Training is under way to ensure a swift launch after FDA approval, though hospital committee reviews may affect initial adoption speed. "

WRAPSODY 2025 Revenue Potential
Q: What revenue might WRAPSODY generate in 2025?
A: They remain conservative on forward revenue expectations for WRAPSODY and will provide further details in an upcoming virtual meeting post-approval. "